To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia

To evaluate the efficacy and safety of Z-338 in subjects with Functional Dyspepsia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Functional Dyspepsia

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Leuven University

Leuven, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects presenting diagnosis of FD as defined by the Rome II
Subjects presenting postprandial fullness and/or Early satiety should be the most bothersome symptom

Exclusion criteria

Treatment and study plan

Z-338

Drug

Primary outcomes

Global subject Outcome Assessment

Time frame: 12 month

Secondary outcomes

Individual symptom

Time frame: 12 month

Sponsors and collaborators

Lead sponsor

Zeria Pharmaceutical

Industry

Registry information

Important dates

Study start: 2006
Primary completion: 2009
Study completion: 2009
First posted: May 10, 2006
Registry last updated: May 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed